CTRI/2024/08/072197尚未招募2 期
An Interventional Trial to Evaluate the Impact of GLUBLOC™ on HbA1c levels, Glycemic Variability and Time in Range in Type 2 diabetic individuals. - NI
INU Energy Pvt Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Age: 25 - 65 years old male and non-pregnant females
- •Diagnosis of Type 2 Diabetes Mellitus for at least 6 months; treated with stable dose of oral anti-diabetic drugs (drugs permitted: metformin, sulfonylureas) for at least 3 months before screening.
- •Participants with HbA1c between 7 to 11 percent
- •Participant willing to provide informed consent and willing to comply with study procedures
排除标准
- •Type 1 Diabetes Mellitus participants.
- •Type 2 Diabetes Mellitus participants on insulin, Thiazolidinediones, GLP-1 agonists, DPP-IV inhibitors, AGI’s and/or SGLT2 inhibitors.
- •Allergy to one or more components of the investigational product or history of food allergies
- •Participant receiving any diabetes specific nutritional food supplement apart from multivitamin/ mineral supplements (Ca/Vit D supplements and B complex syrups) within 15 days prior to study start.
- •Participant taking any herbal/ayurvedic/ alternative medicine preparations that could profoundly affect blood glucose.
- •Females who are nursing / pregnant / are of child - bearing potential and not practicing an acceptable method of birth control / or do not plan to continue using this method throughout the study and do not agree to submit to periodic pregnancy testing during participation in the trial.
- •Participant has evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic or allergic disease, which in the opinion of the investigator, can adversely affect study outcome/s.
- •Participant with active infection in past 30 days.
- •Participant has a history of any episode(s) of severe hypoglycemia (requiring third party assistance), disabling diabetic neuropathy including autonomic neuropathy, gastroparesis or lower limb ulceration or amputation or evidence or history of diabetic complications with significant end organ damage.
- •Participants on any pharmacological therapy of modern or alternative medicine for management of obesity in past 6 months.
- •Participants with history of bariatric surgery.
- •Participant has any major or minor surgery within 30 days prior to screening
研究者
相似试验
已完成
2 期
Counselling by nurse will improve medical adherence, patient satisfaction, sinonasal quality and visual quality of life in post operative patients of pituitary tumors.CTRI/2019/06/019505Postgraduate Institute of Medical Education and Research Chandigarh60
尚未招募
3 期
Karshyahara lauha a potent herbomineral powder to increase Hb or HemoglobiCTRI/2024/08/071906Dr Sunil Sukumar Shirahatti
尚未招募
3 期
A Clinical trial to evaluate the effect of Ayurvedic drugs and Yoga therapy on Male InfertilityCTRI/2021/03/031646BH
尚未招募
2 期
Effect of Inspiratory Muscle Strength Training (IMST) on Blood PressureAmong Older AdultsCTRI/2024/08/071780Fogarty International Center - National Institutes of Health (NIH)
招募中
1 期
VECTORS – A study to evaluate transmural healing as a treatment target in Crohn’s diseaseModerately to Severely Active Crohn’s DiseaseMedDRA version: 20.0Level: PTClassification code: 10011401Term: Crohn's disease Class: 100000004856CTIS2023-509096-16-00Alimentiv Inc.266